Evotec
Alastair Parkes is a seasoned Medicinal Chemist with extensive experience in drug discovery and development, currently serving at Evotec since June 2006. Initially, from 2006 to 2009, Alastair contributed to proprietary CNS drug discovery programs in Evotec's Internal Research department, later focusing on oncology programs in Discovery Collaborations from 2010 to 2013. Prior to Evotec, Alastair was a Post-Doctoral Research Associate at the University of Manchester from 2004 to 2006, collaborating with Professor John Sutherland on nucleotide and carbohydrate chemistry. Alastair began his career with summer placements at GlaxoSmithKline from 1995 to 1999. Alastair holds a D.Phil in Organic Chemistry and an M.Chem in Chemistry, both obtained from the University of Oxford.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.